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DOI 10.1186/s12931-015-0182-xRESEARCH Open AccessChanges in the endurance shuttle walk test in
COPD patients with chronic respiratory failure
after pulmonary rehabilitation: the minimal
important difference obtained with anchor- and
distribution-based method
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Peter J Wijkstra1,4 and Johan B Wempe1,2,4Abstract
Background: Although the endurance shuttle walk test (ESWT) has proven to be responsive to change in exercise
capacity after pulmonary rehabilitation (PR) for COPD, the minimally important difference (MID) has not yet been
established. We aimed to establish the MID of the ESWT in patients with severe COPD and chronic hypercapnic
respiratory failure following PR.
Methods: Data were derived from a randomized controlled trial, investigating the value of noninvasive positive
pressure ventilation added to PR. Fifty-five patients with stable COPD, GOLD stage IV, with chronic respiratory failure
were included (mean (SD) FEV1 31.1 (12.0) % pred, age 62 (9) y). MID estimates of the ESWT in seconds, percentage
and meters change were calculated with anchor based and distribution based methods. Six minute walking
distance (6MWD), peak work rate on bicycle ergometry (Wpeak) and Chronic Respiratory Questionnaire (CRQ) were
used as anchors and Cohen’s effect size was used as distribution based method.
Results: The estimated MID of the ESWT with the different anchors ranged from 186–199 s, 76–82% and
154–164 m. Using the distribution based method the MID was 144 s, 61% and 137 m.
Conclusions: Estimates of the MID for the ESWT after PR showed only small differences using different anchors in
patients with COPD and chronic respiratory failure. Therefore we recommend using a range of 186–199 s, 76–82%
or 154–164 m as MID of the ESWT in COPD patients with chronic respiratory failure. Further research in larger
populations should elucidate whether this cut-off value is also valid in other COPD populations and with other
interventions.
Trial registration: ClinicalTrials.Gov (ID NCT00135538).
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Patients with severe Chronic Obstructive Pulmonary
Disease (COPD) have an impaired exercise capacity,
which is frequently associated with lower physical activ-
ity level [1] and, importantly, with lower quality of life
[2,3] and higher mortality [4]. Therefore, enhancement
of exercise capacity is an important goal of interventions
such as pulmonary rehabilitation (PR) [5] and pharma-
cological treatment [6].
Exercise capacity can be assessed by maximal and sub-
maximal tests, which reflect different pathobiological
properties like sufficient aerobic enzyme systems, muscle
strength, cardiovascular fitness and motivation. Maximal
exercise capacity is commonly assessed with incremental
cycle ergometry or treadmill walking, but these tests are
not very responsive to interventions such as medication
[7] or exercise training [8]. Field walking tests, such as
the six-minute walking distance (6MWD) and endurance
shuttle walk test (ESWT), might better reflect quality of
life and activities of daily living, and therefore might be
more relevant measurements in patients with severe
COPD. The ESWT has a number of advantages com-
pared to the 6MWD. Firstly, the ESWT has been shown
to be very responsive to bronchodilation [9] and PR
[10,11] and might be even more responsive to treatment
than the 6MWD [11,12]. Secondly, the ESWT is less af-
fected by motivation and pacing ability of the patient
than the 6MWD because gate speed is imposed [13,14].
Unfortunately, at this moment it is not clear which
size of change in ESWT could be considered as clinically
relevant. This is important for developing new studies,
for weighing results of interventions, and for clinicians
in evaluating provided care. Until now, only one study
provided some information about the minimally import-
ant difference (MID) of the ESWT [15]. In that study,
the MID was investigated after bronchodilation and PR
using an anchor based (global rating of change) and dis-
tribution based method (half a standard deviation (SD)
of the changes in ESWT time or distance) [15]. The
MID of the ESWT after treatment with salmeterol or
ipratropium bromide was found to be 45–85 seconds.
The anchor based MID of the ESWT after 7 weeks of
PR, however, was not determined.
For this study we used the Chronic Respiratory
Questionnaire (CRQ), peak work rate (Wpeak) and
6MWD as anchors in combination with a distribution
based method. Those anchors were chosen because
they are accepted outcomes of pulmonary rehabilita-
tion and all in some way reflect exercise capacity or
quality of life. The aim of the current study is to de-
termine the MID of the ESWT in patients with severe,
hypercapnic COPD (GOLD IV) following PR with or
without nocturnal non-invasive intermittent positive pres-
sure ventilation (NIPPV).Methods
Study population
A total of 55 patients with stable COPD, GOLD stage
IV, with chronic hypercapnic respiratory failure, were
included in the current analyses. All these patients par-
ticipated in a randomized controlled trial of which the
results were published previously [16,17]. In this study
the additional effect of NIPPV on the effects of PR was
investigated. Seventy-two patients were included in the
study, of which 56 patients completed the rehabilitation
program of 12 weeks. Patients were assigned to rehabilita-
tion with (n = 32) or without NIPPV (n = 24). Inclusion
criteria were a stable clinical condition (no exacerbation
in the four weeks prior to study participation), severe
COPD (FEV1 < 50%pred), hypercapnia at rest (arterial car-
bon dioxide pressure PaCO2 > 6.0 kPa while breathing
room air) and age between 40–80 years. Exclusion criteria
were the presence of cardiac or neuromuscular diseases
limiting exercise tolerance, exposure to NIPPV or PR in
the previous 18 months, or the presence of obstructive
sleep apnoea syndrome (apnoea/hypopnoea index ≥ 10/
hour). The study was approved by the local Medical Ethics
Committee of the University Medical Centre Groningen
and was registered at ClinicalTrials.Gov (ID NCT00135538).
All patients gave written informed consent to participate.
In the current analysis only patients that completed all
measurements (31 in the PR group and 24 in the PR +
NIPPV group) at the start and directly after the rehabilita-
tion program were included.
Study design
At baseline lung function, exercise tolerance and quality
of life were assessed. Thereafter patients started a
12 week period of rehabilitation with or without NIPPV.
The rehabilitation program consisted of strength train-
ing, cycling, walking, inspiratory muscle training, educa-
tion and psychological and/or nutritional support if
necessary as described in detail elsewhere [16,17]. The
exercise training sessions were on three days per week.
NIPPV was initiated in the hospital to train the patients
to use the ventilatory support during the night as long
as possible with a minimum duration of 6 hours. The
adjustment process of NIPPV and the patient compli-
ance afterwards were described in detail in previous
publications [16,17]. After the intervention period of
12 weeks measurements of exercise tolerance and qual-
ity of life were repeated. Apnea/hypoapnea index was
measured with overnight polygraphy prior to the study.
Measurements
All lung function measurements were performed after
bronchodilation. Forced expiration volume in 1 second
(FEV1) and forced vital capacity (FVC) were assessed by
spirometry according to ERS criteria [18]. Total lung
Table 1 Baseline characteristics
(n = 55)
Age, y 62.0 (9)
BMI, kg/m2 27.5 (6.1)
FEV1,l 0.84 (0.34)
FEV1 %pred, % 31.1 (12.0)
FEV1/FVC, % 31.8 (9.2)
TLC, l 7.27 (1.41)
RV/TLC, % 63.9 (9.1)
PO2, kPa 8.14 (1.18)
PCO2, kPa 6.85 (0.73)
Wpeak, W 28.1 (18.5)
VO2 peak, ml/min 250 (56)
ISWT, m 160 (40–450)
ESWT, m 240 (40–1160)
ESWT, s 257 (81–1220)
6MWD, m 315 (80–615)
CRQ total 80.3 (17.8)
CRQ dyspnoea 16.7 (4.8)
CRQ fatigue 13.68 (4.5)
CRQ emotion 31.5 (7.9)
CRQ mastery 18.4 (5.0)
Values or expressed as mean (SD) or median (range). BMI: body mass index;
FEV1: forced expiration volume in 1 second; FVC: forced vital capacity; TLC:
total lung capacity; RV: residual volume; Wpeak: peak work rate; ISWT:
incremental shuttle walk test; ESWT: endurance shuttle walk test; 6MWD: six
minute walking distance; CRQ: Chronic Respiratory Questionnaire.
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by body plethysmography [19].
Cycle ergometer tests were performed after optimal
bronchodilation. First, daytime resting arterial blood
gases on room air were taken from all patients while
lying (Rapid lab type 865, Siemens, USA). The incre-
mental cycle ergometer test was performed using a
1-minute incremental protocol, using 5 Watt incre-
ments. Patients were seated on the bicycle, respired
through a mouth piece and wore a nose clip during
the test. Minute ventilation, tidal volume, breathing
frequency and oxygen uptake were measured continuously
(Oxycon Pro Viasys, Bilthoven, the Netherlands). Maximal
workload (Wpeak) was defined as the highest work level
reached and maintained for at least 30 seconds.
The ESWT was performed on a 10 m long course at a
speed corresponding with 85% of VO2 peak, which was
estimated from an earlier performed incremental shuttle
walking test [20]. For both tests a practice walk was
done during the run-in period of the study. Patients
were instructed to walk as long as possible at the speed
that was dictated by the auditory signal. The test was
ended when a patient was more than 0.5 m away from
the marker before the signal was given on two successive
shuttles, or when he or she indicated to be exhausted.
The 6MWD was assessed indoors on a 40 m long
course. Patients used their usual walking aids and, if
applicable, their usual ambulatory oxygen therapy during
the test. The test assistant gave standardized encourage-
ments every 30 seconds and told the patient after 2 and
after 4 minutes that he/she was 2 and 4 minutes on his/
her way [21]. All patients performed a practice test first,
the results of which were discarded.
During the walking tests supplemental oxygen was
permitted, but conditions were the same at all tests. The
walking tests were not stopped because of desaturation.
Quality of life was assessed with the interviewed ver-
sion of the Chronic Respiratory Questionnaire [22]. The
CRQ is a widely used disease specific questionnaire
which has shown to be reliable and valid in COPD pa-
tients [23].
Minimal important difference calculation methods and
statistical analysis
The minimal important difference can be estimated in
various ways and generally a combination of methods is
recommended [24]. In the current study we used both
anchor based and distribution based methods. For the
anchor based method we used three measures with
an established MID: The 6MWD (25 m) [25], Wpeak
(4 Watt) [26,27] and the CRQ (10 points in total
score) [28]. Spearman’s correlations between improved
ESWT on the one hand and improved 6MWD, Wpeak
and CRQ on the other hand had to be > 0.30 allowinglinear regression analyses. There is no consensus on what
an appreciable association between the outcome variable
and the anchor should be. However, a correlation of 0.30
is considered to be the lower limit [24,26,29]. Afterwards,
the MID of the ESWT was derived from substituting the
MID of the anchors in the regression line of ΔESWT and
Δ anchor. A distribution-based method was used to com-
pare the change in outcome variable with an arbitrary
measure of variability, which in this study was the effect
size, using the following equation: 0.5 *SD (ΔESWT). The
analyses were performed on pooled treatment groups
as the separate analyses of the two treatment arms
(PR or PR +NIPPV) showed similar associations, thereby
increasing statistical power. The MID of the ESWT was
expressed as change in time, percentage change from
baseline (time or meters) and change in meters.
All statistical analyses were performed using Scientific
Package of Social Sciences (SPSS) version 18.0. P-values
<0.05 were considered to be significant.
Results
The baseline characteristics of the 55 COPD patients
(42% female) are shown in Table 1.
Table 3 Anchor-based MID of ESWT (s and %) using CRQ
and 6MWD
anchor MID ESWT 95% CI
MID ESWT (s) Wpeak 198.9 163.7–234.1
CRQ 186.4 147.4–225.4
6MWD 199.1 153.3–245.0
MID ESWT (%) Wpeak 81.2 65.3–97.0
CRQ 75.9 59.2–92.6
6MWD 82.2 63.5–100.9
MID ESWT (m) Wpeak 163.6 129.1–198.2
CRQ 153.7 115.6–191.8
Wpeak: peak work rate; CRQ: Chronic Respiratory Questionnaire; 6MWD: six
minute walking distance; ΔESWT: change in endurance shuttle walking test.
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For further analysis correlations >0.30 were used. These
were shown for ESWT change in absolute time (ΔESWTs)
and % change from baseline (ΔESWT%) with all three
anchors, 6MWD, Wpeak and CRQ, and for ESWT change
in meters (ΔESWTm) with the CRQ and Wpeak. (Table 2
and Additional file 1: Figure S1) The CRQ total score
showed higher correlations with ESWT change than the
CRQ subscales and therefore CRQ total score was used in
the regression analysis.
Anchor based and distribution based estimates of the
MID of the ESWT
Table 3 shows the MID estimates and 95% confidence
intervals (in seconds, percentage and meters) derived
from the linear regression equations of ΔESWT and
Δanchor (Additional file 2: Table S1). The MID esti-
mate of ESWTm using the 6MWD as an anchor was
not calculated because ΔESWTm and Δ6MWD cor-
related <0.30. The MID estimates calculated with the
distribution based method were 145 s for ΔESWTs,
61.4% for ΔESWT% and 137 m for ΔESWTm.
Discussion
In this population of patients with severe COPD and
chronic hypercapnic respiratory failure, who followed PR
(with or without NIPPV), we estimated the MID for the
ESWT. Using three different anchors we found MID
estimates ranging from 186–199 s, 76–82% and 154–
164 m. The anchors Wpeak and 6MWD provided almost
identical results. In contrast, the MID based on statistical
variability of the effect size was somewhat lower: 61%,
145 s and 137 m.
All anchors used in our study meet the criteria of a
good anchor [24]. These criteria, applied to this field, are
firstly: the anchor should have an established MID
derived from multiple high quality studies, including
many well characterized COPD patients, using multiple
methods, and agreeing about the final MID estimate.Table 2 Spearman’s Correlation of ESWT with possible
anchors
ΔESWT (s) ΔESWT (%) ΔESWT (m)
Δ Wpeak, W 0.568 0.525 0.610
Δ CRQ total 0.449 0.441 0.428
Δ CRQ dyspnoea 0.313 0.299 0.305
Δ CRQ fatigue 0.373 0.328 0.350
Δ CRQ emotion 0.363 0.351 0.353
Δ CRQ mastery 0.389 0.338 0.381
Δ 6MWD, m 0.307 0.318 0.275
Values printed bold p < 0.05.
Wpeak: peak work rate; CRQ: Chronic Respiratory Questionnaire; 6MWD: six
minute walking distance; ΔESWT: change in endurance shuttle walking test.Secondly, the anchor should be derived from a com-
parable COPD population. Thirdly, the anchor should
somehow reflect the perception of improved exercise
capacity. Finally the anchor should correlate highly with
changes in ESWT. The anchors used in this study will
be discussed in this perspective.
The first anchor was the Chronic Respiratory Ques-
tionnaire. The CRQ has a widely accepted MID of 10
points on the total score (or 0.5 per question), which has
been estimated with different methods [28,30,31]. In
addition, the CRQ has served as an anchor for establish-
ing MID’s of other measurement tools as well, such as
the Hospital Anxiety and Depression Scale and the feel-
ing thermometer [32,33]. Correlations of CRQ change
and ESWT change showed rho values > 0.40 and the
CRQ could therefore be used as an anchor. Although
the CRQ does not reflect the exact same concept as the
ESWT, it is a measure that reflects the patients per-
ception of health status, which agrees with the MID
concept.
The second anchor was Wpeak. Two studies esti-
mated the MID for Wpeak using anchor based or
distribution based methods and expert opinions. Both
studies suggest a MID of 4 Watt. [26,27] Correlations
of Wpeak change and ESWT change showed rho
values > 0.50 suggesting that Wpeak could be used as
an anchor. In addition, Wpeak reflects exercise capacity as
does the ESWT, and in both tests patients reach a similar
peak performance [34].
The 6MWD also seems a suitable anchor as its MID
has been established in different subgroups of COPD
patients using different interventions including a PR
intervention. We chose to use the MID of 25 m, based
on two studies, one in a slightly milder COPD popula-
tion (age 70 y, FEV1 52% pred) after PR [25], and one in
a more severe COPD population (age 66.4, FEV1 26.9%
pred), showing an MID of 26 m after surgical lung vol-
ume reduction [26]. Another feature demonstrating the
6MWD to be a suitable anchor is that it reflects exercise
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ent way. Associations of 6MWD change with ESWT
change were just high enough to use it as an anchor,
therefore this estimation should be taken with some cau-
tion. On the other hand, the MID estimated using the
6MWD as anchor was very similar to the MID estimated
using the CRQ and Wpeak.
To verify the MID values found with the anchor based
method we also used a distribution based method. The
latter method should only be used complementary to an
anchor based method as it does not fit with the primary
aim of the MID concept, which is to indentify an effect
size that is relevant in the perception of the patient [24].
In our study the distribution based method showed
lower values for the MID than the anchor based method.
It has been shown before that distribution based methods
tend to underestimate the MID when based on a single
study [32].
The MID values estimated with the CRQ, Wpeak and
6MWD were very close to one another (see Table 3).
The MID estimated with the distribution based method
was somewhat lower (144 s, 61% and 137 m). In line
with the literature we recommend to use MID values
based on the anchor based method [24]. We prefer to
use the MID estimates in seconds and %, and not meters
as a change of 100 meters at a low speed has a different
value in clinical perspective than a change of 100 m at a
high speed.
The estimation of the MID of the ESWT after PR has
been investigated in one other study in patients with less
severe COPD (FEV1 48% pred). In this study, global rat-
ing of change was used as an anchor, comprising of one
question. To our opinion, the anchors in our study were
suitable as well because the CRQ, 6MWD and to a lesser
degree Wpeak, are outcome measures with an estab-
lished MID and showed correlations >0.30 with ESWT
change. However, we realize that our anchors might not
reflect exactly the same construct as the ESWT. Pepin
et al. only used a distribution based method showing an
MID of 186 seconds or 136%, because they decided that
associations with the global rating of change were too low
to be used to estimate an anchor based MID after PR.
Though we studied a different population than Pepin,
our anchor based MID was surprisingly similar to their
distribution based estimate, at least for the change in
ESWT (s).
Of course we were very interested in how our results
are in comparison to other PR intervention studies that
used the ESWT as an outcome measure. Several studies
were found and they all showed significant improve-
ments in ESWT after intervention [10,35-39]. The stud-
ies included patients with quite similar mean age (60–75
years) and mean FEV1 (37.5–63.0% predicted) and dem-
onstrated mean ESWT improvements between 138–378seconds, 15–100% and 106–393 meters [10,35-39].
These change values were consistent with our MID
estimates (ranging from 186–199 s, 76–82% and 154–
164 m).
A major difference with the patients included in the
present analysis is that the patients in the current ana-
lysis all suffered from chronic hypercapnic respiratory
failure. Probably, the differences found in mean ESWT
changes in these studies are due to differences in COPD
population, study design and efficacy of the intervention.
A strong point of our study is that we used an anchor
based method including three different anchors as well as
a distribution based method to determine the MID of the
ESWT. Another strong feature is that the correlations of
the ESWTchange with all anchors were above 0.30, allow-
ing us to use the anchors in a meaningful way.
A limitation of this study might be the relatively small
number of patients in the study and the fact that this
was a very specific group of COPD patients, namely
those with severe COPD and chronic respiratory failure.
Therefore, it might not be appropriate to generalize our
results straight to the entire COPD population as the
MID might differ between populations with other phe-
notypes and disease stages. A remark should also be
made about the confidence intervals for the MID esti-
mates we found, which were quite wide. This hinders
firm conclusions. Another limitation of this study is that
we did not use a global rating of change as an anchor to
estimate the MID of the ESWT. For example by asking
the patient the question: ‘In comparison with your previ-
ous test, how would you rate your performance on the
current test? Using a 7-point Likert scale to rate this
performance.
Conclusions
In conclusion, in patients with severe hypercapnic COPD
undergoing PR with or without NIPPV, the MID estimates
for the ESWT ranged from 186–199 s, 76–82% and 154–
164 m using different anchors (CRQ, Wpeak, 6MWD).
Estimates of the MID of the ESWT using 6MWD and
Wpeak as anchors provide almost identical results. This
MID construct needs further validation in larger and dif-
ferent subgroups of COPD patients.
Additional files
Additional file 1: Figure S1. a-i. Scatterplots of change in ESWT versus
change in anchor variable.
Additional file 2: Table S1. Regression equations used to calculate MID
values.
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